Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

USFDA action on Indoco Plants: Angel Broking

Posted On: 2017-04-04 21:01:03

Views of Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking):

"The USFDA had inspected Indoco Remedies manufacturing facilities (Plant II & Plant III, L-32,33,34 Verna Industrial Estate Area, Verna, Goa), from August 31st 2016 to September 4th, 2016.As an outcome of this inspection, the facility received 6 observations in Form 483, which do not pertain to data integrity. Based on the review of compliance response, USFDA accepted company's response to 4 observations. However, FDA remains concerned with respect to 2 observations, pertaining to one specific product, for which the company is contract manufacturer, for one of its customers and consequently, the company has received a warning letter from USFDA dated 27th March 2017. The company is fully committed in resolving the issue and will respond at the earliest.

As per the company, warning letter pertains to issue of leakages in the product Latanoprost, which has sales of INR 25cr p.a. Revenue exposure of plant under warning to U.S. is INR 75cr, out of the total U.S. business of INR 110cr. In terms of number of ANDAs pending from Plant III is 9, while number of ANDAs pending from Plant II is 18. While the company does not expect disruptions in supplies as of now, it expects the delay in approvals in future. AS of now the damage is very minimal to the US operations of the company and even in the worst come situation (if all the INR 75cr sales are under pressure), the impact on the net profit is expected to around 6-7%. We maintain our NEUTRAL rating on the stock."

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.228.95 as compared to the previous close of Rs. 249.95. The total number of shares traded during the day was 226701 in over 7647 trades.

The stock hit an intraday high of Rs. 234 and intraday low of 209. The net turnover during the day was Rs. 49993818.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Earnings Update - KEC International (KECI IN) - Robust quarter; driven by strong growth in railway segment - CSEC Research
Earnings Update - Karur Vysya Bank (KVB IN) - Growth in loan book picks-up; margin surprises positively - CSEC Research
Earnings Update - PI Industries (PI IN) - Robust margins expansions - CSEC Research
Earnings Update - V-Guard Industries (VGRD IN) - Robust performance across segments - CSEC Research
Result Update: JSW Steel - Accumulate - TP Rs.215 - Kotak
Result Update: Pidilite Industries Ltd - Sell - TP Rs.660 - Kotak
Result Update: CENTURY PLYBOARDS LTD - BUY - TP Rs.277 - Kotak
Result Update: Entertainment Network (India) Ltd)- REDUCE - TP Rs.770 - Kotak
Result Update: Dish TV - SELL - TP Rs.82 - Kotak
Result Update: Cummins India Limited - ACCUMULATE - TP Rs. 1,018 - Kotak
Result Update: GRASIM INDUSTRIES LTD - ACCUMULATE - TP Rs. 1,236 - Kotak
Result Update: Bajaj Auto Limited - ACCUMULATE - TP Rs. 3,124 - Kotak
Result Update: Motherson Sumi Systems Limited - REDUCE - TP Rs. 439 - Kotak
Result Update: Tata Power - Accumulate - TP Rs. 89 - Kotak
Result Update: Hindustan Media Ventures Ltd. - Accumulate - TP Rs.307 - Kotak
Result Update: DB Corp - BUY - TP Rs.572 - Kotak
Banks : RBI notification casts light on measures aimed at resolving bad loans - Kotak
Result Update: GUJARAT STATE PETRONET LTD (GSPL) - ACCUMULATE - TP Rs.182 - Kotak
Result Update: Praj Industries- Reduce - TP Rs.81 - Kotak
Result Update: (Voltas Ltd) - Accumulate - TP Rs.506 - Kotak
Views on Tech Mahindra Ltd 4QFY2017 Results: Angel Broking
Views on Sun Pharmaceutical Industries Limited 4QFY2017 Results: Angel Broking
GlaxoSmithKline Pharmaceuticals - 4QFY2017 Result Update - Angel Broking
Result Update: Engineers India Ltd (EIL) BUY TP Rs.195 - Kotak
Result Update: NAGARJUNA CONSTRUCTION COMPANY (NCC) BUY TP Rs.107 - Kotak
Result Update: Tata Motors (TAMO) BUY TP Rs.539 - Kotak
Views on Lupin Limited 4QFY2017 Results: Angel Broking
Strategy: GST: The finishing line is finally here - Kotak
Views on Cipla Limited 4QFY2017 Results: Angel Broking
Technology: Job losses-beyond the noise - Kotak
Result Update: Mangalore Refinery and Petrochemicals Ltd. (MRPL) - ACCUMULATE - TP Rs.144 - Kotak
Result Update: NIIT Ltd (NIIT) - BUY - TP Rs.103 - Kotak
Strategy: GST: The final lap - Kotak
Views on GlaxoSmithKline Pharmaceuticals Limited 4QFY2017 Results: Angel Broking
GST could throw some light on market in upcoming week : Amrapali Aadya Trading & Investments
What the GST rates mean for key sectors in India? - Angel Broking
Earnings Update - HCL Technologies(HCLT IN) - Industry leading growth ahead - CSEC Research
Earnings Update - Dr Reddy's Laboratories (DRRD IN) - High competition & continued pricing pressure hammered global sales - CSEC Research
Earnings Update - KPIT Technologies (KPIT IN) - Growth momentum is gaining - CSEC Research
Earnings Update - NIIT Technologies(NTL IN) - Healthy order book - CSEC Research
Earnings Update - South Indian Bank (SIB IN) - Asset quality improves on sale to ARC - CSEC Research
Earnings Update - CEAT Ltd. (CEAT IN) - Margin declined due to higher RMC - CSEC Research
Earnings Update - Bajaj finance (BAF IN) - Continues to be consistent in its core performance - CSEC Research
Earnings Update - JK Cement (JKCE IN) - Robust quarter driven by better realization - CSEC Research
Earnings Update - JKL Cement (JKLC IN) - Cost saving measures to drive the margins - CSEC Research
Earnings Update - Kajaria Ceramics (KJC IN) -Revenue growth led by volume - CSEC Research
HCL Technologies - 4QFY2017 Result Update - Angel Broking
Result Update: Kajaria Ceramics Ltd - ACCUMULATE - TP Rs.757 - Kotak
Result Update: Colgate Palmolive (India) Ltd. - SELL - TP Rs.980 - Kotak
Result Update: Chennai Petroleum Corporation Ltd (CPCL) - ACCUMULATE - TP Rs.455 - Kotak


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017